Potential of outpatient steroid therapy in elderly patients with early COVID-19Observational Study Published on 2022-10-012023-07-09 Journal: Aging Clinical and Experimental Research [Category] COVID19(2023년), [키워드] all-cause mortality Corticosteroids COVID-19 elderly Outpatient Pneumonia [DOI] 10.1007/s40520-022-02181-1 PMC 바로가기 [Article Type] Observational Study
Symptomatology and imaging findings in early post-Covid period: A comparative study in older vs younger patientsArticle Published on 2022-10-012023-07-10 Journal: Experimental gerontology [Category] COVID19(2023년), [키워드] COVID-19 Follow-up imaging Outpatient recovery Symptom [DOI] 10.1016/j.exger.2022.111907 PMC 바로가기
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surgeArticle Published on 2022-09-302022-11-15 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 진단, [키워드] 95% CI all-cause mortality B.1.1.529 clinical trial Cohort component control patient COVID-19 COVID-19 outpatient Effectiveness evaluate events Hospitalization Hospitalized incidence less likelihood no difference omicron Outpatient positive Primary outcome receive receiving reduction in Remdesivir retrospective cohort study risk SARS-CoV-2 secondary outcome severe COVID-19 significantly significantly lower Symptom symptom onset the primary endpoint therapy treated [DOI] 10.1093/jac/dkac256 PMC 바로가기
Activity of ertapenem/zidebactam (WCK 6777) against problem EnterobacteralesArticle Published on 2022-09-302022-11-16 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 비임상, [키워드] 1:1 active against activity administration breakpoint Dilution E. coli Escherichia coli evaluated experiments group healthcare increasingly indicated Infection inhibited isolate Klebsiella KPC Laboratory material MDR National nosocomial Outpatient over Parenteral pathogen Patient proportion regimen SARS-CoV-2 secondary submitted Support susceptibility Trial will drive [DOI] 10.1093/jac/dkac280 PMC 바로가기
Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, JapanArticle Published on 2022-09-222023-07-09 Journal: Japanese journal of infectious diseases [Category] COVID19(2023년), [키워드] antibody healthcare worker Outpatient SARS-CoV-2 Seroprevalence [DOI] 10.7883/yoken.JJID.2022.155
Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-09-202022-11-15 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, [키워드] 30-Day mortality Activation Admission Analysis Bacterial Biomarker blood sample C5a cascade clinically suspected comparable complement complement system Concentration Control control group controls COVID-19 COVID-19 patient disease E-selectin elevated endothelial Endothelial cell endothelial cells Endothelium evaluate excluded females galectin-3 galectin-3. ICAM-1 ICU Inflammatory inflammatory condition Inpatient male non-infectious nonspecific occurred outcome Outpatient Patient Pneumonia presenting prospective cohort study recruited respiratory viral infections SARS-CoV-2 SARS-COV-2 infection SC5b-9 significantly significantly higher single-center study VCAM-1 [DOI] 10.3389/fimmu.2022.941742 PMC 바로가기
Clinical significance and role of coinfections with respiratory pathogens among individuals with confirmed severe acute respiratory syndrome coronavirus-2 infectionArticle Published on 2022-09-022022-11-15 Journal: Frontiers in Public Health [Category] SARS, 치료기술, [키워드] 229E acute respiratory syndrome Adenovirus AdV age analyzed average C-reactive protein (CRP cause children Clinical data clinical feature clinical picture Clinical significance Coinfection collected Combination complications Coronavirus-2 COVID-19 CRP detect determine Diseases distribution highest HKU1 Hospital stay hospitalized patient individual Infection Influenza influenza A Influenza virus involved lymphocyte métapneumovirus NL63 OC43 other respiratory virus outcome Outpatient parainfluenza virus Patient patients with SARS Prevalence Prevent proportion respiratory pathogen respiratory syncytial virus respiratory virus respiratory viruses rhinovirus RSV SARS CoV-2 SARS-CoV-2 SARS-CoV-2 positive patient Screening seasonal coronavirus specimen tested the disease the mean Treatment Viral load virus was determined was used worsening [DOI] 10.3389/fpubh.2022.959319 PMC 바로가기
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent PlasmaArticle Published on 2022-09-012022-11-15 Journal: Annals of internal medicine [Category] SARS, 진단, 치료기술, [키워드] AABB addition Admission advancement antibody assessment Biotherapy CCP clinical Clinical practice close contact convalescent plasma Coronavirus disease 2019 COVID-19 development Disease progression effective Evidence Good Clinical Practice GRADE framework guideline high risk Hospitalized hospitalized patient immunosuppressed patient Immunosuppression infected patient lack Meta-analysis moderate Neutralizing titer Outpatient Participants Potential treatment Practice Prophylactic Randomized controlled trial RCT RCTs recommendation recommendations SARS-CoV-2 SARS-CoV-2 antibody severe disease Standard of care symptom onset systematic review transfused uninfected with COVID-19 [DOI] 10.7326/M22-1079 PMC 바로가기
Reduction and persistence of co-circulating respiratory viruses during the SARS-CoV-2 pandemicSARS-CoV-2 대유행 기간 동안 동시 순환 호흡기 바이러스의 감소 및 지속성Article Published on 2022-09-012022-09-12 Journal: American journal of infection control [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] collected COVID-19 evaluate Infection infection control Measures molecular Molecular respiratory panel Nasopharyngeal swab North Outpatient pandemic performed persistence positive respiratory respiratory virus respiratory viruses rhinovirus SARS-CoV-2 symptomatic syndromic testing tested the SARS-CoV-2 virus [DOI] 10.1016/j.ajic.2022.06.008 PMC 바로가기 [Article Type] Article
SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbiditiesArticle Published on 2022-09-012022-11-15 Journal: Journal of clinical pharmacy and therapeutics [Category] COVID19(2023년), SARS, 진단, [키워드] 30-Day mortality BAM bamlanivimab black changed clinical trials Cohort cohort of patient Combination Comorbidity comparable coronavirus disease COVID-19 etesevimab etesevimab. evaluated groups high-risk patient Hospitalization incidence laboratory-confirmed LOS male median age Median BMI monoclonal antibody monotherapy Neutralizing outcome outcomes Outpatient Patient provided receiving recent reduced Result retrospective cohort study SARS-CoV-2 SARS-CoV-2 neutralizing antibody secondary shown significantly symptom onset treated [DOI] 10.1111/jcpt.13694 PMC 바로가기